Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neural Transmission
Published in: Journal of Neural Transmission 1/2013

01-01-2013 | Movement Disorders - Review article

Mild cognitive impairment in Parkinson disease: heterogenous mechanisms

Author: Kurt A. Jellinger

Published in: Journal of Neural Transmission | Issue 1/2013

Login to get access

Abstract

Cognitive impairment is common in Parkinson disease (PD), with long-term longitudinal studies reporting that most PD patients develop dementia. A high proportion of patients with PD and mild cognitive impairment (MCI) progress to dementia within a short time. Impairments occur in a range of cognitive domains, but single-domain impairment is more common than multiple one, non-amnestic more common than amnestic impairment. Although the term MCI applied to PD (PD-MCI) is not without controversy due to the lack of uniform diagnostic consensus criteria, the biological validity of PD-MCI is supported by many recent studies that show heterogenous mechanisms in the clinical presentation, neuropsychology, neuroimaging, biomarkers, and neuropathology, suggesting abnormal metabolic network activities involving several cortical and subcortical nervous systems. Prospective studies using specific biomarkers, including amyloid imaging, and cerebro-spinal fluid biomarkers are warranted for an exact diagnosis and prognostic assessment of early cognitive deficits in PD patients.
Literature
Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G (2009) Cognitive impairment in incident, untreated Parkinson disease: the norwegian parkwest study. Neurology 72:1121–1126PubMedCrossRef
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75:1062–1069PubMedCrossRef
Aarsland D, Bronnick K, Fladby T (2011) Mild cognitive impairment in Parkinson’s disease. Curr Neurol Neurosci Rep 11:371–378PubMedCrossRef
Adler CH, Beach TG (2010) Variability of diffuse plaques and amyloid angiopathy in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol 120:831–832
Adler CH, Caviness JN, Sabbagh MN, Shill HA, Connor DJ, Sue L, Evidente VG, Driver-Dunckley E, Beach TG (2010) Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol 120:827–828PubMedCrossRef
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270–279PubMedCrossRef
Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E (2010) CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the norwegian parkwest study. J Neurol Neurosurg Psychiatry 81:1080–1086PubMedCrossRef
American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington
Ash EL, Korczyn AD (2011) Is amnestic mild cognitive impairment a useful concept? Aging Health 7:107–122CrossRef
Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D (2011) Cognitive impairment in nondemented Parkinson’s disease. Mov Disord 26:2483–2495PubMedCrossRef
Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G (2008) Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Aging 12:61S–65SPubMedCrossRef
Beach TG, Adler CH, Lue LF, Sue L, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL 3rd, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG, Arizona Parkinson’s Disease Consortium (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117:613–634PubMedCrossRef
Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS (2005) Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 64:834–841PubMedCrossRef
Beyer MK, Janvin CC, Larsen JP, Aarsland D (2007) A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78:254–259PubMedCrossRef
Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis ChA, Davis JG, Moore RY, Dekosky ST (2006) Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253:242–247PubMedCrossRef
Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE (2011) Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 52:848–855PubMedCrossRef
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
Britt WG III, Hansen AM, Bhaskerrao S, Larsen JP, Petersen F, Dickson A, Dickson C, Kirsch WM (2011) Mild cognitive impairment: prodromal Alzheimer’s disease or something else? J Alzheimers Dis 27:543–551PubMed
Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes K, Tekin S, Aarsland D (2006) Attentional deficits affect activities of daily living in dementia-associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry 77:1136–1142
Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2009) Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 30:682–690PubMedCrossRef
Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22:1272–1277PubMedCrossRef
Coen RF (2011) Neuropsychological assessment of mild cognitive impairment/prodromal Alzheimer’s disease. Aging Health 7:155–162CrossRef
Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505
Costello A, Al Khamees H, Moriarty J, Hulse N, Malik I, Selway R, Clough C, Ashkan K, Michael S (2011) Non-amnestic mild cognitive impairment is a prominent aspect in Parkinson’s disease patients being considered for deep brain stimulation. Basal Ganglia 1:213–220CrossRef
Dalrymple-Alford JC, Livingston L, MacAskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord 26:629–636PubMedCrossRef
Defrancesco M, Marksteiner J, Deisenhammer EA, Hinterhuber H, Weiss EM (2009) Association of mild cognitive impairment (MCI) and depression. Neuropsychiatr 23:144–150PubMed
Farlow MR, Cummings J (2008) A modern hypothesis: The distinct pathologies of dementia associated with Parkinson’s disease versus Alzheimer’s disease. Dement Geriatr Cogn Disord 25:301–308
Frank G, Hennig-Fast K, Klunemann HH, Schmitz G, Greenlee MW (2011) Differential impact of ApoE epsilon4 on cortical activation during famous face recognition in cognitively intact individuals and patients with amnestic mild cognitive impairment. Alzheimer Dis Assoc Disord 25:250–261PubMedCrossRef
Ganguli M, Dodge HH, Shen C, DeKosky ST (2004) Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 63:115–121PubMedCrossRef
Ganguli M, Snitz BE, Saxton JA, Chang CC, Lee CW, Vander Bilt J, Hughes TF, Loewenstein DA, Unverzagt FW, Petersen RC (2011) Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 68:761–767PubMedCrossRef
Gauthier S, Touchon J (2005) Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol 62:1164–1166 Discussion 1167PubMedCrossRef
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367:1262–1270PubMedCrossRef
Goldman JG, Litvan I (2011) Mild cognitive impairment in Parkinson’s disease. Minerva Med 102:441–459PubMed
Goldman JG, Stebbins GT, Bernard B, Goetz CG (2011) Clinical Differences among PD-MCI Subtypes (abs). Ann Neurol 70(suppl 15):S16
Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60:729–736PubMedCrossRef
Haldenwanger A, Eling P, Kastrup A, Hildebrandt H (2010) Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer’s disease. J Alzheimers Dis 22:971–980PubMed
Han JW, Lee SB, Kim TH, Park JH, Lee JJ, Huh YS, Choi EA, Choe JY, Do YJ, Lee DY, Kim KW (2011) Functional impairment in the diagnosis of mild cognitive impairment. Alzheimer Dis Assoc Disord 25:225–229PubMedCrossRef
Hanfelt JJ, Wuu J, Sollinger AB, Greenaway MC, Lah JJ, Levey AI, Goldstein FC (2011) An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the national Alzheimer’s coordinating center. Am J Geriatr Psychiatry 19:940–950PubMedCrossRef
Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K (2010) Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 31:357–367PubMedCrossRef
Haroutunian V, Hoffman LB, Beeri MS (2009) Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosci 11:171–179PubMed
Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK (2011) Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77:1619–1628PubMedCrossRef
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844PubMedCrossRef
Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD (2005) Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65:1716–1722PubMedCrossRef
Hirsch E (2008) Is the cholinergic system involved in cognitive impairment in Parkinson’s disease? (abs.). In: 6th International Congress on Mental Dysfunctions and Other Non-Motor Features in Parkinson’s Disease and Related Disorders, Dresden, Oct 16–19, 2008. Kenes International Geneva, pp Abstract on CD-ROM
Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D (2008) Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70:1470–1477PubMedCrossRef
Israeli-Korn SD, Massarwa M, Schechtman E, Strugatsky R, Avni S, Farrer LA, Friedland RP, Inzelberg R (2010) Mild cognitive impairment is associated with mild parkinsonian signs in a door-to-door study. J Alzheimers Dis 22:1005–1013PubMed
Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC (2009) Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer’s disease: implications for sequence of pathological events in Alzheimer’s disease. Brain 132:1355–1365PubMedCrossRef
Jack CR Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS (2010) Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease. Brain 133:3336–3348PubMedCrossRef
Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006) Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 21:1343–1349PubMedCrossRef
Jauhiainen AM, Kangasmaa T, Rusanen M, Niskanen E, Tervo S, Kivipelto M, Vanninen RL, Kuikka JT, Soininen H (2008) Differential hypometabolism patterns according to mild cognitive impairment subtypes. Dement Geriatr Cogn Disord 26:490–498PubMedCrossRef
Jellinger KA (2009) Editorial: The neurological substrate of Parkinson disease dementia. J Mov Disord 23:1–3
Jellinger KA (2010a) Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis 7:112–115PubMedCrossRef
Jellinger KA (2010b) Neuropathology in Parkinson’s disease with mild cognitive impairment. Acta Neuropathol 120:829–830 author reply 831PubMedCrossRef
Jellinger KA (2010c) The neuropathologic substrate of Parkinson disease dementia. Acta Neuropathol 119:151–153
Jellinger KA, Attems J (2008) Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115:427–436PubMedCrossRef
Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 109:329–339PubMedCrossRef
Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63:674–681PubMedCrossRef
Jicha GA, Abner E, Schmitt FA, Cooper GE, Stiles N, Hamon R, Carr S, Smith CD, Markesbery WR (2008) Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord 26:187–192PubMedCrossRef
Jicha GA, Abner EL, Schmitt FA, Kryscio RJ, Riley KP, Cooper GE, Stiles N, Mendiondo MS, Smith CD, Van Eldik LJ, Nelson PT (2011) Preclinical AD workgroup staging: pathological correlates and potential challenges. Neurobiol Aging 33(3):622.e1–622.e16CrossRef
Kalaitzakis ME, Pearce RK (2009) The morbid anatomy of dementia in Parkinson’s disease. Acta Neuropathol 118:587–598
Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200–1213PubMedCrossRef
Klepac N, Trkulja V, Relja M, Babic T (2008) Is quality of life in non-demented Parkinson’s disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol 15:128–133
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75:230–238PubMedCrossRef
Lee JE, Park HJ, Song SK, Sohn YH, Lee JD, Lee PH (2010) Neuroanatomic basis of amnestic MCI differs in patients with and without Parkinson disease. Neurology 75:2009–2016PubMedCrossRef
Liepelt-Scarfone I, Graeber S, Feseker A, Baysal G, Godau J, Gaenslen A, Maetzler W, Berg D (2011) Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson’s disease. Parkinsons Dis 2011:540843PubMed
Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D (2011) MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord 10:1814–1824CrossRef
Luck T, Luppa M, Briel S, Riedel-Heller SG (2010) Incidence of mild cognitive impairment: a systematic review. Dement Geriatr Cogn Disord 29:164–175PubMedCrossRef
Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS (2010) Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 64:65–73PubMedCrossRef
Marder K (2010) Cognitive impairment and dementia in Parkinson’s disease. Mov Disord 25(Suppl 1):S110–S116PubMedCrossRef
Markesbery WR (2010) Neuropathologic alterations in mild cognitive impairment: a review. J Alzheimers Dis 19:221–228PubMed
Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR (2006) Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38–46PubMedCrossRef
Martin SB, Smith CD, Collins HR, Schmitt FA, Gold BT (2010) Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiol Aging 31:1099–1106PubMedCrossRef
Martinez-Horta S, Kulisevsky J (2011) Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”? J Neural Transm 118:1185–1190PubMedCrossRef
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRef
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMedCrossRef
Mitchell AJ, Shiri-Feshki M (2008) Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis. J Neurol Neurosurg Psychiatry 79:1386–1391PubMedCrossRef
Molano J, Boeve B, Ferman T, Smith G, Parisi J, Dickson D, Knopman D, Graff-Radford N, Geda Y, Lucas J, Kantarci K, Shiung M, Jack C, Silber M, Pankratz VS, Petersen R (2010) Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 133:540–556PubMedCrossRef
Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J (2010) CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 25:2682–2685PubMedCrossRef
Morris JC, Fulling K (1988) Early Alzheimer’s disease: diagnostic considerations. Arch Neurol 45:345–349PubMedCrossRef
Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58:397–405PubMedCrossRef
Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006) The uniform data set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20:210–216PubMedCrossRef
Mufson EJ, Binder L, Counts SE, DeKosky ST, deTolledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW (2011) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol 123:31–37
Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239–1245PubMedCrossRef
Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B, Brugnolo A, Canepa C, Drosos GC, Sambuceti G, Rodriguez G (2009a) Amnestic mild cognitive impairment in Parkinson’s disease: a brain perfusion SPECT study. Mov Disord 24:414–421PubMedCrossRef
Nobili F, De Carli F, Frisoni GB, Portet F, Verhey F, Rodriguez G, Caroli A, Touchon J, Morbelli S, Guerra UP, Dessi B, Brugnolo A, Visser PJ (2009b) SPECT predictors of cognitive decline and Alzheimer’s disease in mild cognitive impairment. J Alzheimers Dis 17:761–772PubMed
O’Dwyer L, Lamberton F, Bokde AL, Ewers M, Faluyi YO, Tanner C, Mazoyer B, O’Neill D, Bartley M, Collins DR, Coughlan T, Prvulovic D, Hampel H (2011) Using diffusion tensor imaging and mixed-effects models to investigate primary and secondary white matter degeneration in Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis 26:667–682PubMed
Oishi K, Akhter K, Mielke M, Ceritoglu C, Zhang J, Jiang H, Li X, Younes L, Miller MI, van Zijl PC, Albert M, Lyketsos CG, Mori S (2011) Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer’s disease. Front Neurol 2:54PubMed
Okonkwo OC, Mielke MM, Griffith HR, Moghekar AR, O’Brien RJ, Shaw LM, Trojanowski JQ, Albert MS (2011) Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol 68:113–119PubMedCrossRef
Pa J, Boxer A, Chao LL, Gazzaley A, Freeman K, Kramer J, Miller BL, Weiner MW, Neuhaus J, Johnson JK (2009) Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol 65:414–423PubMedCrossRef
Palmer K, Backman L, Winblad B, Fratiglioni L (2008) Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry 16:603–611PubMedCrossRef
Panza F, Frisardi V, Capurso C, D’Introno A, Colacicco AM, Imbimbo BP, Santamato A, Vendemiale G, Seripa D, Pilotto A, Capurso A, Solfrizzi V (2010) Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry 18:98–116PubMedCrossRef
Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, Amboni M, Erro R, Vitale C, Caprio MG, Pellecchia MT, Brunetti A, De Michele G, Salvatore M, Barone P (2011) Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 77:1357–1362PubMedCrossRef
Pasotti C, Minafra B, Zangaglia R, Sinforiani E, Bertaina I, Pacchetti C (2011) Mild cognitive impairment in Parkinson’s disease (abs.). Basal Ganglia 1:174
Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50:743–755PubMedCrossRef
Petersen RC, Morris JC (2005) Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 62:1160–1163 Discussion 1167PubMedCrossRef
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308PubMedCrossRef
Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, Jicha GA, Ivnik RJ, Smith GE, Tangalos EG, Braak H, Kokmen E (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672PubMedCrossRef
Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, Smith GE, Jack CR Jr (2009) Mild cognitive impairment: ten years later. Arch Neurol 66:1447–1455PubMedCrossRef
Plassman BL, Langa KM, McCammon RJ, Fisher GG, Potter GG, Burke JR, Steffens DC, Foster NL, Giordani B, Unverzagt FW, Welsh-Bohmer KA, Heeringa SG, Weir DR, Wallace RB (2011) Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 70:418–426PubMedCrossRef
Rabin LA, Borgos MJ, Saykin AJ, Wishart HA, Crane PK, Nutter-Upham KE, Flashman LA (2007) Judgment in older adults: development and psychometric evaluation of the test of practical judgment (TOP-J). J Clin Exp Neuropsychol 29:752–767PubMedCrossRef
Reid WG, Hely MA, Morris JG, Loy C, Halliday GM (2011) Dementia in Parkinson’s disease: a 20-year neuropsychological study (sydney multicentre study). J Neurol Neurosurg Psychiatry 82:1033–1037PubMedCrossRef
Reisberg B, Ferris SH, de Leon MJ, Franssen ESE, Kluger A, Mir P, Borenstein J, George AE, Shulman E, Steinberg G, Cohen J (1988) Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res 15:104–114CrossRef
Riederer P, Bartl J, Laux G, Grunblatt E (2011) Diabetes type II: a risk factor for depression-Parkinson–Alzheimer? Neurotoxic Res 19:253–265CrossRef
Rinne JO, Nagren K (2010) Positron emission tomography in at risk patients and in the progression of mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis 19:291–300PubMed
Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA (2008) The mayo clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiol 30:58–69CrossRef
Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A (2009) Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment—proof of concept. Dement Geriatr Cogn Disord 27:194–200PubMedCrossRef
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A et al (1993) Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology 43:250–260PubMedCrossRef
Sabbagh MN, Shah F, Reid RT, Sue L, Connor DJ, Peterson LK, Beach TG (2006) Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 63:1771–1776PubMedCrossRef
Saito Y, Murayama S (2007) Neuropathology of mild cognitive impairment. Neuropathology 27:578–584PubMedCrossRef
Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 27:1372–1384PubMedCrossRef
Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501–1508PubMedCrossRef
Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ (2011) Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis 24:547–557PubMed
Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA (2009) The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 66:200–208PubMedCrossRef
Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR Jr, Weiner MW (2009) MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain 132:1067–1077PubMedCrossRef
Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP (2011) A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 32(12):2322.e5–e18
Shi M, Huber BR, Zhang J (2010) Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 20:660–671PubMedCrossRef
Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C (2010) CSF amyloid beta 1–42 predicts cognitive decline in Parkinson disease. Neurology 75:1055–1061PubMedCrossRef
Silbert LC, Kaye J (2010) Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol 20:646–653PubMedCrossRef
Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA (2010) Mild cognitive impairment in Parkinson’s disease: subtypes and motor characteristics. Parkinsonism Relat Disord 16:177–180PubMedCrossRef
Sonnen JA, Montine KS, Quinn JF, Breitner JC, Montine TJ (2010) Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. J Alzheimers Dis 19:301–309PubMed
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:280–292PubMedCrossRef
Stephan BC, Matthews FE, Hunter S, Savva GM, Bond J, McKeith IG, Ince P, Brayne C (2012) Neuropathological profile of mild cognitive impairment from a population perspective. Alzheimer Dis Assoc Disord, (in press). doi:10.​1097/​WAD.​1090b1013e31822f​c31824d
Storandt M, Grant EA, Miller JP, Morris JC (2006) Longitudinal course and neuropathologic outcomes in original vs. revised MCI and in pre-MCI. Neurology 67:467–473PubMedCrossRef
Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Lon L, Lyketsos CG (2009) Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry 70:584–592PubMedCrossRef
Tröster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18:103–119PubMedCrossRef
Tröster AI (2011) A Precis of Recent Advances in the Neuropsychology of Mild Cognitive Impairment(s) in Parkinson’s Disease and a Proposal of Preliminary Research Criteria. J Int Neuropsychol Soc 8:1–14
Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC (2009) Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73:1469–1477
Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI (2011) Progression of tau pathology in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Am J Pathol 179:2533–2550PubMedCrossRef
Wallin A, Gothlin M, Gustavsson M, Zetterberg H, Eckerstrom C, Blennow K, Edman A, Lind K, Nordlund A, Rolstad S (2011) Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations. Dement Geriatr Cogn Disord 32:193–197PubMedCrossRef
Ward A, Arrighi HM, Michels S, Cedarbaum JM (2012) Mild cognitive impairment: Disparity of incidence and prevalence estimates. Alzheimers Dement 8:14–21
Weintraub D, Doshi J, Koka D, Davatzikos C, Siderowf AD, Duda JE, Wolk DA, Moberg PJ, Xie SX, Clark CM (2011) Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 68:1562–1568PubMedCrossRef
Weintraub D, Dietz N, Duda JE, Wolk DA, Doshi J, Xie SX, Davatzikos C, Clark CM, Siderowf A (2012) Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease. Brain 135:170–180
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130:1787–1798PubMedCrossRef
Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009a) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958–2969PubMedCrossRef
Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA (2009b) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s disease. J Neurol 256:493–498PubMedCrossRef
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment—beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med 256:240–246PubMedCrossRef
Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65:557–568PubMedCrossRef
Zgaljardic DJ, Foldi NS, Borod JC (2004) Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm 111:1287–1301PubMedCrossRef
Zhang H, Trollor JN, Wen W, Zhu W, Crawford JD, Kochan NA, Slavin MJ, Brodaty H, Reppermund S, Kang K, Mather KA, Sachdev PS (2011) Grey matter atrophy of basal forebrain and hippocampus in mild cognitive impairment. J Neurol Neurosurg Psychiatry 82:487–493PubMedCrossRef
Zihl J, Reppermund S, Thum S, Unger K (2010) Neuropsychological profiles in MCI and in depression: differential cognitive dysfunction patterns or similar final common pathway disorder? J Psychiatr Res 44:647–654PubMedCrossRef
Metadata
Title
Mild cognitive impairment in Parkinson disease: heterogenous mechanisms
Author
Kurt A. Jellinger
Publication date
01-01-2013
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 1/2013
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-012-0771-5

Other articles of this Issue 1/2013

Journal of Neural Transmission 1/2013 Go to the issue

Biological Child and Adolescent Psychiatry - Review article

A systematic review on olfaction in child and adolescent psychiatric disorders

Basic Neurosciences, Genetics and Immunology - Short communication

Comparison of analgesic effects of single versus repeated injection of botulinum toxin in orofacial formalin test in rats

Basic Neurosciences, Genetics and Immunology - Original Article

Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment

Basic Neurosciences, Genetics and Immunology - Original Article

Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia

Basic Neurosciences, Genetics and Immunology - Review article

70th Birthday symposium of Prof. Dr. Riederer: autologous adult stem cells in ischemic and traumatic CNS disorders

Biological Psychiatry - Review article

The effects of most commonly prescribed second generation antidepressants on driving ability: a systematic review